Transactivation of PTGS2 by PAX5 signaling potentiates cisplatin resistance in muscle-invasive bladder cancer cells

Cisplatin (CDDP)-based systematic chemotherapy remains the mainstay of treatment for muscle-invasive bladder cancer (MIBC). However, acquired resistance to CDDP, a multifactorial process governed by an array of signals acting at different levels, is the major problem in BC treatment. Here, we report...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biochemical and biophysical research communications 2018-09, Vol.503 (4), p.2293-2300
Hauptverfasser:	Dong, Bing-wei, Zhang, Wei-bo, Qi, Shu-min, Yan, Chang-you, Gao, Juan
Format:	Artikel
Sprache:	eng
Schlagworte:	60 APPLIED LIFE SCIENCES BLADDER CHROMATIN Cisplatin Cisplatin - pharmacology Cyclooxygenase 2 - genetics Drug Resistance, Neoplasm - genetics Humans INFLAMMATION LUCIFERASE Muscle Neoplasms - secondary Muscle-invasive bladder cancer (MIBC) Neoplasm Invasiveness PAX5 PAX5 Transcription Factor - genetics PTGS2 Signal Transduction TRANSCRIPTION FACTORS Transcriptional Activation Transcriptional regulation Tumor Cells, Cultured Urinary Bladder Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!